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Abstract
 
Using patient data from a unique single source outbreak of hepatitis B virus (HBV) infection, we
have characterized the kinetics of acute HBV infection by monitoring viral turnover in the serum
during the late incubation and clinical phases of the disease in humans. HBV replicates rapidly
 
with minimally estimated doubling times ranging between 2.2 and 5.8 d (mean 3.7 
 
6 
 
1.5 d). Af-
 
ter a peak viral load in serum of nearly 10
 
10
 
 HBV DNA copies/ml is attained, clearance
 
 
 
of HBV
DNA follows a two or three phase decay pattern with an initial rapid decline characterized by
 
mean half-life (
 
t
 
1/2
 
)
 
 
 
of 3.7 
 
6 
 
1.2 d, similar to the 
 
t
 
1/2
 
 observed in the noncytolytic clearance of
covalently closed circular DNA for other hepadnaviruses. The final phase of virion clearance oc-
curs at a variable rate (
 
t
 
1/2
 
 of 4.8 to 284 d) and may relate to the rate of loss of infected hepato-
cytes. Free virus has a mean 
 
t
 
1/2
 
 of at most 1.2 
 
6 
 
0.6 d. We estimate a peak HBV production rate
of at least 10
 
13
 
 virions/day and a maximum production rate of an infected hepatocyte of 200–
1,000 virions/day, on average. At this peak rate of virion production we estimate that every pos-
sible single and most double mutations would be created each day.
Key words: acute hepatitis B • kinetics • cytotoxic T lymphocytes • mutation • hepatocyte
 
Introduction
 
The kinetics of acute hepatitis B virus (HBV)
 
1
 
 infection
have previously been studied in animal models but, until
now, there has been limited quantitative data in humans
with acute infection (1, 2) and none based on the analytical
sensitivity of PCR-based assays. Thus, the quantitation of
the kinetics of self-limited acute infection has not been ad-
equately studied. We have recently described a large, com-
mon source outbreak of acute hepatitis B, caused by trans-
mission of a single HBV variant by “autohemotherapy”.
An investigation to identify all cases, to characterize the ep-
idemic, and to limit the transmission of the virus was begun
as soon as the first patients were diagnosed. As a result of
the early identification of patients infected with HBV in
this outbreak, we could analyze data from several patients
acutely infected from the same source before symptoms,
and seroconversion to anti-HBe, i.e., during both the late
incubation and clinical phases of the disease. In this paper,
we report on a study of the dynamics of primary HBV in-
fection in humans and estimate rates of viral production
and clearance. From serial measurements of serum HBV
 
DNA, we estimate viral doubling times (
 
t
 
d
 
) and the time
between infection and peak viral level. After the peak, viral
levels decay in several phases which may correlate with un-
derlying biological mechanisms encompassing decay of co-
valently closed circular (ccc)DNA, loss of infected hepato-
cytes, and clearance of free virus.
 
Materials and Methods
 
Patients and Data.
 
HBV DNA and alanine transaminase
(ALT) levels in serum were obtained for seven patients with pri-
mary HBV infection (Fig. 1). ALT was measured by an in-house
radioimmunoassay. Hepatitis B surface antigen (HBsAg), hepatitis
B e antigen (HBeAg), anti-HBe antibody (anti-HBe), and anti-
body to hepatitis B core (anti-HBc) status (Fig. 2) were also deter-
mined by commercial enzyme immunoassay kits (Abbott Labora-
tories). Patient 7, who developed chronic hepatitis B infection,
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was identified in the incubation phase of infection and subse-
quently was commenced on the reverse transcriptase inhibitor
lamivudine. We have reported previously that this outbreak of
HBV was acquired from contamination of a multidose saline vial
used in autohemotherapy (3). Sequencing of HBV DNA, from se-
rum samples obtained at presentation, showed identical nucleotide
sequence for the surface and core encoding regions in all of these
patients. Thus, all patients were infected with an identical isolate
of HBV and had a common source and mode of transmission.
 
HBV DNA Quantification.
 
Serum samples for HBV DNA
quantification were obtained prospectively and stored at 
 
2
 
20
 
8
 
C.
To reduce interassay variability, all samples derived from each pa-
tient were analyzed in the same assay, incorporating up to 41
samples. HBV DNA concentrations in serum were measured by
the Amplicor HBV Monitor test (Roche Diagnostics Systems)
which is a quantitative PCR based assay and the manufacturer’s
instructions were followed throughout. In brief, a 104-bp se-
quence of the precore/core region of HBV is amplified along
with an internal standard (IS) to monitor the efficiency of the am-
plification reaction, one of the primers being biotinylated. Six
HBV DNA standards (range 0–10
 
6
 
 copies) are amplified at the
same time. The amplicons are denatured and the biotinylated
strand immobilized on a streptavidin-coated microwell plate.
DNP-labeled oligonucleotide probes specific for HBV and the IS
are then hybridized to the immobilized amplicons. After washing,
the bound probe is quantitated using an ELISA procedure with
anti-DNP–alkaline phosphatase conjugate and 
 
para
 
-nitrophen-
ylphosphate substrate. Absorbance of sample/HBV probe and
sample/IS probe is measured at 405 nm. The HBV to IS signal
ratio is calculated to correct for sample to sample differences in
amplification efficiency. Finally, the ratios from the unknowns
 
are compared with a standard curve generated from the HBV
standards and the HBV concentrations of each sample are calcu-
lated. The assay quantitates virus between 4 
 
3
 
 10
 
2
 
 and 4 
 
3
 
 10
 
7
 
particles per ml. Samples exceeding the upper limit were diluted
in normal human serum and retested. Comparative quantitation
of HBV DNA by this assay have been reported previously (4, 5).
 
Results
 
Viral t
 
d
 
 and Time of Infection.
 
Patients 1, 2, 5, and 6
were identified in the incubation period when viral levels
were below their eventual peak. For each of these patients,
the 
 
t
 
d
 
 of serum HBV DNA (
 
t
 
d
 
) was estimated and ranged
between 2.2 and 5.8 d with a mean of 3.7
 
 6 
 
1.5 d. Because
data was collected near the peak viral load, the true 
 
t
 
d 
 
may
have been underestimated.
The time of infection relative to the viral peak, 
 
t
 
o
 
, was
estimated assuming that the infecting inoculum contained
10
 
3
 
 HBV DNA particles (similar to that of a needle stick
injury [6]) and distributed throughout 3 liters of serum
(Fig. 1). It seemed reasonable to assume that the amount of
HBV-contaminated blood introduced into the multidose
saline vial used to spread the infection was small because
there was no obvious discoloration. This analysis yielded a
mean time to infection before the viral peak of 127 
 
6 
 
46 d.
Analyzing the patient with the fastest 
 
t
 
d
 
, patient 2, where
we may have caught the earlier stages of viral rise and
hence obtained a more accurate estimate of the initial 
 
t
 
d
 
,
the estimated time until peak virus level after infection was
80 d. This is consistent with the 60–110-d incubation pe-
riod for the majority of HBV infections in humans (7) and
the 8-wk time before viral peak for chimpanzees inoculated
with a larger HBV dose (8). Furthermore, in patient 2, the
 
t
 
o
 
 was calculated to be around January 29, a date which co-
incides with her attendance for autohemotherapy on a
weekly basis from January 12 to February 16. This provides
some validation of our assumption that the infecting inocu-
lum contained 
 
z
 
10
 
3
 
 HBV DNA particles, but unfortu-
Figure 1. Serum log10 HBV DNA copies per ml and serum log10 ALT
IU/liter values are displayed over the period of observation. In only one
patient was there a serious comorbid condition: patient 7 who had cryp-
togenic organizing pneumonitis for which she was maintained on long-
term steroid therapy before her autohemotherapy. Patient 7 failed to clear
HBsAg, perhaps because of immunosuppresion, and was commenced on
lamivudine 100 mg daily, which is denoted by “L” in the graph. Four pa-
tients were identified in the late incubation phase of acute infection when
the initial serum HBV DNA was below the eventual peak. td for serum
HBV DNA were estimated by determining the rise in log10 viral level be-
tween the first and second measurements (d). The estimated to before
peak serum HBV DNA was determined using these td.
Figure 2. HBsAg, HBeAg, anti-HBe, and anti-HBc for the seven pa-
tients. Black denotes a positive assay, white a negative assay, and gray in-
dicates time between a positive assay and a negative assay. 
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nately the inoculum was not available for examination and
confirmation of the exact HBV content. However, we cal-
culate that each 10-fold error in the initial concentration of
HBV would change the estimate of the time from infection
to the viral peak by 12.3 d. Because patient 2 could only
have been infected while she attended for autohemother-
apy, our estimate for her date of infection is at most off by
18 d, and thus the potential miscalculation of the dose is at
most by a factor of 10
 
1.5
 
.
 
Half-Lives of Viral Decay.
 
The decline in serum HBV
DNA was multiphasic with an initial rapid decline over
several days followed by a slower decline over several
weeks. In patients 2 and 6, the transition between these
phases was characterized by a rapid fall in viral DNA,
which may represent a combination of both phases or a
separate biological process. Using linear regression we esti-
mated the rate of viral decay for each dominant phase (Fig.
3), and calculated the corresponding half-lives.
The initial decline in serum viremia was exponential as
demonstrated by a straight-line fit to the data on a semilog-
arithmic plot with a mean 
 
R
 
2 
 
statistic of 0.90 (excluding pa-
tient 7 who was on lamivudine therapy). The first phase
decay of viral DNA had a mean half-life of 3.7 
 
6 
 
1.2 d.
The final phase decay of viral DNA had a range of esti-
mated half-lives that varied from 4.8 to 284 d, although we
have limited confidence in the long half-life estimates. If
we
 
 
 
consider only those final phases where the regression
lines have an 
 
R
 
2
 
 statistic of 0.8 or better, then the range of
half-life
 
 
 
values was 4.8 to 17 d with a mean of 12 
 
6 
 
6 d.
This range is consistent with the half-life of infected hepa-
tocytes as estimated using mathematical models in studies of
patients chronically infected with HBV treated with lami-
vudine (half-lives
 
 
 
of 10–100 d; reference 9) or adefovir
(half-lives
 
 
 
of 18 
 
6
 
 7 d; reference 10).
 
Free Virus Half-Life.
 
Based on drug perturbation exper-
iments (9, 10) as well as estimates of the half-life of other
viruses, the half-life of HBV in serum is expected to be
short and clearance of HBV should be the fastest kinetic
process that we observe. We thus estimated the half-life of
free virus by examining the rate of change of HBV DNA
levels between individual data points. We excluded from
the calculations patients 3, 4, and 5 because the time be-
tween data points was relatively large and would tend to
mask the faster half-lives. A histogram of the half-lives in
the range 0–6 d is shown in Fig. 4.
The histogram in Fig. 4 displays two clusters of half-
lives, the shortest between 0.3 and 2.7 d, and the second
between 3.7 and 5.8 d. The second cluster is confirmation
of the first phase half-life of 3.7 
 
6 
 
1.2 d discussed above.
Under the assumption that the shortest half-lives seen in
the data correspond to the decay of free virus (9, 10), we
estimated the mean virion half-life by fitting a lognormal
distribution to the data in the first cluster (Fig. 4). This
gave a mean half-life of free virus of 1.2 
 
6 
 
0.6 d. The me-
dian of this set of half-lives was 1.1 d. This is consistent
with the values estimated in treatment studies for chronic
HBV showing a free virus half-life
 
 
 
of 1.1 d (for adefovir
[10]) and 1 d (for lamivudine [9]). As the smallest time be-
tween data points was 1 d, there is an inherent bias towards
underestimating these decay rates by our method. Conse-
quently, the value derived here provides an underestimate
of the decay rate and therefore an overestimate of the half-
life. The same caveat can be placed on the literature esti-
mates, where viral levels were measured every 7 d in one
study (10), and on days 0, 2, 7, and weekly thereafter in
the other (9).
 
Peak Viral Levels and Rate of Virion Production.
 
For the
five patients where the first serum HBV DNA measure-
ment was at or before the peak level, the maximum log
 
10
 
viral level was determined. The mean maximum log
 
10
 
 viral
Figure 3. Serum HBV DNA half-lives, linear regression lines, and R2
statistics for the two dominant phases of viral decay for each patient. End-
points for regression are noted with filled circles.
Figure 4. Histogram of half-lives in the range 0–6 d for patients 1, 2, 6,
and 7, obtained by determining the slopes between consecutive data
points. Each slope was counted several times depending on the magnitude
of the viral change. For example, if a half-life of 1 d was measured be-
tween time points 10 d apart, it was counted 10 times as many as a half-
life of 1 d measured between time points 1 d apart. 
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level was 9.5 
 
6 
 
0.5. The three largest log
 
10
 
 values were 9.8,
9.6, and 10.
A possible explanation for the uniform maximum serum
HBV DNA levels seen, and indeed the stable high level for
the chronically infected patient 7, is that at the peak of in-
fection nearly all hepatocytes are infected. This would be in
agreement with animal studies in which immunohis-
tochemical analysis of liver specimens using antibody di-
rected against the HBV core antigen has shown a 
 
.
 
95% in-
fection of hepatocytes in acutely infected woodchucks (11).
If in acute infection most hepatocytes become infected,
then we can estimate the daily production of virus by an
infected cell. When the peak viral load is reached the
amount of virus in the serum is neither increasing nor de-
creasing so that the infection process is in steady state
where the rate of viral production equals the rate of virion
clearance. If there are 
 
I 
 
infected cells, each producing an
average of 
 
p 
 
virions per day, then the rate of virion produc-
tion is 
 
pI
 
. If the peak viral burden is 
 
V 
 
and free virions are
cleared at rate 
 
c 
 
per virion, then the total rate of clearance is
 
cV
 
. The estimated average half-life of free virions of 1.2 d
implies that 
 
c 
 
5 
 
0.58 d
 
2
 
1
 
. HBV is clearly present in the 3 li-
ters of serum (3 
 
3
 
 10
 
3
 
 
 
ml) of the prototypical 70-kg per-
son. Its presence in the rest of body water is not well char-
acterized. Thus, we obtain as a minimal estimate that in a
person with a peak value of 10
 
10
 
 HBV DNA/ml, 
 
V 
 
5
 
 3 
 
3
 
10
 
13
 
 virions. If virus is present in all 15 liters of body water
at the same concentration as serum, then 
 
V 5 15 3 1013
virions. Thus, the daily clearance (and daily production at
steady state) cV is between 1.7 3 1013 and 8.7 3 1013 viri-
ons. If there are 1011 hepatocytes in a typical adult liver (12)
and 85% are infected, then to attain a peak viral load that is
at steady state each infected hepatocyte would need to pro-
duce 200–1,000 virions per day. Virions are produced via
transcription of cccDNA within the nucleus of infected
hepatocytes forming RNA pregenomes that are subse-
quently reverse transcribed to form the virion HBV DNA
(13). If there are 10–50 cccDNA per infected hepatocyte
(14), we deduce that each cccDNA gives rise to a daily
production of 4–100 new extracellular hepatitis B virions.
This deduction does not take into account possible sub-
populations of human cccDNA with potentially differing
transcriptional activity, as has been reported for duck HBV
(DHBV) DNA (15).
Basic Reproductive Number. The basic reproductive
number,  R0, is an estimate of the number of secondary in-
fections that arise from one infected cell over the course of
its life span at the beginning of infection when cells suscep-
tible to infection (target cells) are not depleted. If R0 is .1,
then the infection grows, whereas if R0 is ,1 then the in-
fection dies out. From a standard model of viral infection
that has been applied to simian immunodeficiency virus
(SIV [16]) and HIV (17) infection in which it is a assumed
that there is a delay of t days from the infection of a cell to
the production of progeny virions, one finds that R0 5
(1 1 r0/d) exp (r0t), where r0 is the initial growth rate of
the virus and d is the loss rate of an infected cell by death or
other mechanisms. Using the estimates of the viral td given
in Fig. 1 we can estimate r0, as by definition td 5 ln 2/r0 5
0.693/r0. If we further assume that the final phase of viral
decay reflects the loss of infected cells, then from the half-
lives reported in Fig. 3 we can estimate d, as by definition
half-life 5 0.693/d. For patient 6 the estimate of the final
phase half-life is not reliable, but for patients 1, 2, and 5 the
R2 statistic suggests that the estimates shown in Fig. 3 are
valid. Computing the R0 for these patients assuming a 1-d
delay between infection and viral production, we find R0 5
3.1, 7.5, and 4.4, for patients 1, 2, and 5, respectively, with
a mean of 5.0. These estimates are most likely underesti-
mates of R0, as the number of target cells may have been
reduced by the time the patients were first identified and
our estimate of r0 may be an underestimate of the true ini-
tial viral growth rate. Patient 2, the patient with the lowest
initial viral load and hence the patient for whom the esti-
mate of initial viral growth may be most accurate, has R0 5
7.5. These estimates suggest that early in acute infection
each HBV-infected cell will infect five or more other cells.
Discussion
For patients 1, 2, and 6 (Fig. 1), the initiation of clinical
symptoms of acute hepatitis B infection coincided with the
peak or the initial decline in serum HBV DNA levels. At
this stage, symptoms were mild and consisted only of non-
specific lethargy, malaise, myalgia, and headache. By the
time jaundice set in, 2–6 wk after the peak in serum HBV
DNA, symptoms were deteriorating and viral levels were
substantially reduced to z105–107 copies/ml.
Interestingly, a faster viral td appeared to correlate with
the severity of acute infection. Hence, patient 2 with the
shortest td became considerably jaundiced with a serum
bilirubin peaking at 847 mmol/ml (normal range 5–17
mmol/ml) and experienced a decline in hepatic synthetic
function with a serum albumin of 27 g/liter (normal range
35–50 g/liter) and a prolonged prothrombin time of 24.7 s
(normal range ,16 s). This was in contrast to patients 1
and 6, with td of 3.2 and 3.6 d, respectively, who retained
normal hepatic synthetic function though they did become
jaundiced with serum bilirubin as high as 429 mmol/ml
and 98 mmol/ml, respectively. Patient 5 with the longest td
of 5.8 d had a relatively mild illness, neither developing
jaundice nor impairment of hepatic synthetic function.
However, due to the limited sample size, these observa-
tions have no statistical power.
In this study we are able to characterize the kinetics of
HBV clearance using a quantitative, sensitive assay for
HBV DNA. The reason for the rapid first phase (3.7 6 1.2 d)
and subsequent phases of viral clearance are, however, un-
clear from our data. The resolution of acute hepatitis B in-
volves a complex interplay of innate and adaptive immune
responses and cellular and humoral immunity. In animal
models, it has been suggested that the mechanism underly-
ing initial viral clearance is the noncytopathic removal or
inhibition, possibly by cytokines, of cccDNA replenish-
ment (8). In our study, the mean half-life for the first phase
of viral clearance is consistent with values obtained in ani-851 Whalley et al.
mal models for the half-life of cccDNA (18, 19). This sug-
gests that the mechanism underlying the first phase of viral
decay may indeed be related to clearance of cccDNA;
however, we cannot exclude the possibility of inhibition of
downstream steps in the viral life cycle, such as viral RNA,
but proof of this requires direct experimental evidence. We
have not made measurements of intrahepatic replicative in-
termediates of HBV DNA, nor of intrahepatic cellular im-
mune responses. Thus, the sequential role of innate immu-
nity, cytokine-mediated downregulation of HBV DNA,
antigen-specific immune responses, and antibody neutral-
ization can only be speculated on; however, quantitative
analysis hints at their importance. The nonspecific symp-
toms experienced by patients as virus titre starts to fall are
similar to those experienced by patients treated with IFN-a,
suggesting a role for cytokine-mediated noncytolytic
downregulation of the infection. However, proof would
require accurate, repeated measurements of cytokines and
replicative intermediates of hepatitis B viral DNA within
the liver of acutely infected patients, and intrahepatic cy-
tokine concentrations, but these studies, in patients with
acute resolving hepatitis B, are ethically inadmissible.
The cccDNA is the transcriptional template for HBV
replication (13, 14, 20). The loss of replicative templates
thus would be expected to decrease the ability of infected
cells to produce hepatitis B virions, and hence serum viral
DNA should decrease accordingly. Thus, the administra-
tion of a reverse transcriptase inhibitor would abrogate the
replenishment of the cccDNA pool, resulting in a decline
of serum HBV DNA as cccDNA decays or cells harboring
HBV cccDNA die. Patient 7, who remained negative for
anti-HBe antibodies, was started on the reverse transcriptase
inhibitor lamivudine. In support of the argument that the
first phase of viral clearance is due to noncytopathic re-
moval or inhibition of cccDNA replenishment, lamivude
treatment resulted in a rate of decline of serum HBV DNA
similar to the rate of viral decline observed during the first
phase in patients not treated with lamivudine.
HBV is thought to be a noncytopathic virus and that cy-
totoxic T lymphocytes mediate clearance of HBV-infected
cells through a cytolytic process (21, 22). Serum ALT is a
surrogate marker of cytolysis of hepatocytes (23, 24). Con-
sistent with the proposed noncytopathic nature of HBV, we
observed for patients 2 and 6 that until the peak viral load
was reached they remained asymptomatic with normal se-
rum ALT (Fig. 1). For patients 1, 2, 3, 4, and 6, serum ALT
peaked at 14 6 6 d after the peak in serum HBV DNA
level. By the time the peak serum ALT was achieved there
was at least a one log, that is 90%, fall in the serum HBV
DNA level. Therefore, our data suggests that the initial
clearance of HBV is a process commenced before the main
cytolytic loss of infected hepatocytes. This is in agreement
with recent evidence from Guidotti et al. (8) that indicates
in the chimpanzee 90% of acutely HBV-infected hepato-
cytes are cleared of infection by noncytolytic processes.
We have recently studied cellular immune responses in
five HLA-A2–positive patients identified in this outbreak,
with patients 1 to 5 in the study by Webster et al. (25) cor-
responding to patients 1, 4, 6, 2, and 7, respectively, of this
study. Quantification of HBV-specific CD81 cells, in
blood, using HLA class I tetramers, suggest that adaptive
immune mechanisms are present during the incubation
phase, at least 4 wk before symptoms (25). Our results have
also suggested that the pattern of reduction in HBV repli-
cation is not directly proportional to tissue injury during
acute hepatitis B in man (25). As virus-specific immune re-
sponses and significant reductions in viral replication are
seen during the incubation phase, it is likely that some im-
munological events central to viral control occur before
symptomatic disease. Thus, overall our data are in general
agreement that noncytolytic processes may contribute to
the initial control of the virus but mechanisms involving
cytolysis are also involved at this early stage. It is of note
that in each of the patients that we studied, the initial fall
from peak viral load was associated with some elevation of
ALT. However, given that the peak ALT occurred 14 6 6 d
after the peak in serum HBV DNA level, the cytolytic
mechanisms of viral clearance may take longer to initiate
than noncytolytic mechanisms and may play a greater role
once there has been a substantial fall in the serum viral load.
After the initial decline in serum HBV levels, there appears
to be a slower final phase of viral clearance characterized in
a subset of patients by a half-life of 12 6 6 d, that coincides
with previous estimates of the rate of removal by the im-
mune system of infected hepatocytes (9, 10). The fact that
serum aminotransferases are raised during this phase sug-
gests that the latter phase may be related to death of hepa-
tocytes by apoptosis and hepatocellular necrosis.
Antibodies to pre-S1 appear early in acute hepatitis B
and may be important in elimination of viremia (26). We
have not examined whether one of the phases of viral
clearance (perhaps by the inhibition of HBV attachment to
a hepatocyte receptor or the regulation of intrahepatic
DNA levels and viral assembly) could be due to pre-S1 an-
tibody. The pre-S1 protein (large HBsAg protein) is an es-
sential component of the envelope of HBV virions, but is
also found, although in far smaller amounts, on HBV tubu-
lar filaments (but not on 20-nm circular particles [27]). We
have no measure of the relative proportions of mature viri-
ons to filaments in plasma during the phases of acute hepa-
titis B, nor of antigen antibody complexing of anti–pre-S1
to expressed pre-S1, which if present could potentially
limit the usefulness of anti–pre-S1 measurements. How-
ever, recently a good correlation was observed between
pre-S1 antigen measured by enzyme-linked immunoassay,
and HBV DNA measured by the Roche Amplicor assay
(28). Thus, we believe that our measurements of viral ki-
netics are valid, but careful quantitation of pre-S1 antigen,
antibody, and intracellular HBV DNA in animal models
could shed further light on mechanisms of viral clearance in
future studies.
Using a unique cohort of primary HBV-infected pa-
tients, we have characterized the early kinetics of HBV in-
fection, during the late incubation phase and early clinical
period of acute hepatitis B. We have shown that HBV can
double as rapidly as every 2.2 d leading to the creation of852 Kinetics of Acute HBV Infection
viral loads that peak near 1010 HBV DNA copies (or parti-
cles)/ml at times as early as 80 d after infection. Our analy-
sis suggests that even though extremely high serum viral
loads are attained, if the vast majority of hepatocytes be-
come productively infected then each cell need only pro-
duce 200–1,000 virions per day at the peak of infection.
However, as noncytolytic processes diminish cccDNA, we
would predict the virion production rate to drop dramati-
cally. Although the virion production rate in infected hu-
mans is not known, Lin et al. (29) have shown that in
DHBV infection the total DNA load in the liver is z500
copies per cell, which although it includes the DHBV
cccDNA, is in the range that we predict for humans during
acute infection.
Variability in HBV td was observed among patients, even
though the patients were infected from the same source.
More rapid daily replication of HBV appeared to be associ-
ated with an increase in severity of acute hepatitis, suggest-
ing that host factors play an important role in determining
both HBV dynamics and the severity of subsequent liver
disease.
From the estimated HBV td and the half-life estimates of
productively infected cells obtained from an examination
of the final phase of viral decay, we were able to obtain the
first estimates of the R0 for HBV. This number indicates
how many cells are infected by the progeny virions pro-
duced by an infected cell early in acute infection, i.e., be-
fore target cells are depleted. For the three patients for
whom we could do this analysis, R0 ranged between 3.1
and 7.4 with a mean of 5. In HIV infection, R0 has been
estimated as 19.3 (17). Any intervention that reduces R0
below 1 results in fewer than one secondary infected cell
arising from each initial infected cell. Thus, the size of R0
provides an estimate of how difficult it should be to extin-
guish infection via therapy, vaccination, or host response.
The most accurate estimates of the R0 are when target cells
are unlimited. It is therefore likely that the estimates here
are a small underestimate of the true R0, as target cells are
likely to be depleted during the course of acute hepatitis B
infection. However, in keeping with other studies, such as
those for acute HIV infection, it is unlikely that this under-
estimate will substantially increase the value of R0 (17). The
significantly smaller R0 that we report for HBV compared
with that of HIV is in agreement with the observation that
the vast majority of immunocompetent adults that are in-
fected with HBV never develop chronic infection (30) and
the efficacy of HBV vaccination (31).
If R0 can be reduced below 1, say by vaccination, then
infection should die out. However, bile duct cells and ex-
trahepatic compartments may be a reservoir for hepadnavi-
ruses that may harbor virus for long periods, although, at
present, it would appear that in humans, the major burden
of HBV replication occurs in the hepatic compartment (29).
Each virion undergoes reverse transcription before its
expulsion from an infected cell. As HBV reverse tran-
scriptase contains no error correction mechanism, this is an
inherently error-prone process. The in vivo HIV error rate
for reverse transcription is estimated as 3.4 3 1025 base
substitutions per site per replication cycle (32). If we as-
sume conservatively that the error rate for HBV to be
lower at say 1026 base substitutions per site per reverse tran-
scription then we can estimate the likely number of virions
that contain mutations from wild-type. With 3,200 bases in
the HBV genome, the average number of base changes is
0.0032 per reverse transcription and hence per virion. Ac-
cording to the Poisson distribution, we thus expect
z0.32% of new virions to have a single mutation. Our cal-
culations show that .1013 virions are produced daily and
observed in the blood at peak infection. Therefore, we
would expect at least 3.2 3 1010 point mutations to be pro-
duced per day, vastly more than the possible number of dif-
ferent single base changes in the HBV genome (Table I).
Hence, we would expect all possible single base changes to
be produced per day at peak infection. The calculations in
Table I show that this is also true for the majority of double
mutations. This has important consequences for the devel-
opment of mutations that escape the immune response, and
also for mutations that provide resistance to reverse tran-
scriptase inhibitors.
Further characterization of the kinetics of acute HBV in-
fection should lead to better understanding of the biologi-
cal processes underlying the virological, immunological,
and liver pathological aspects of the resulting hepatitis.
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